Okay, let's tackle this question. The question is about the mutation responsible for Gastrointestinal Stromal Tumors (GISTs). I remember that GISTs are a type of sarcoma, and they're associated with mutations in certain genes. The main ones I recall are KIT and PDGFRA.

First, the core concept here is the genetic basis of GISTs. The key is to identify which mutations are most commonly involved. I think KIT mutations are the most common, maybe around 80-90% of cases. Then PDGFRA mutations come next, perhaps around 5-10%. There are some rare cases where other genes might be involved, but those are exceptions.

The correct answer should be KIT. Let me confirm. KIT is a receptor tyrosine kinase, and mutations in this gene lead to constitutive activation, causing uncontrolled cell growth. PDGFRA is similar, also a receptor tyrosine kinase. So both are involved, but KIT is more common. The question is asking for the mutation, so the primary answer is KIT.

Now, looking at the wrong options. If the options include other genes like BRAF, EGFR, or something else, those are not typically associated with GISTs. For example, BRAF mutations are more common in melanomas or some colorectal cancers. EGFR is involved in lung and colorectal cancers. So those would be incorrect. Another possible wrong option could be a gene like HER2, which is more related to breast cancer.

The clinical pearl here is that KIT and PDGFRA mutations are the main drivers, and tyrosine kinase inhibitors like imatinib are the mainstay of treatment. So students should remember that GISTs are driven by these mutations and that targeted therapy is effective. Also, knowing the most common vs. less common mutations can help in diagnosis and treatment planning.

Putting this all together, the correct answer is KIT. The explanation should highlight the role of KIT mutations in the pathogenesis of GISTs, the mechanism of action leading to tumor formation, and why other options are not correct. The clinical pearl emphasizes the importance of these mutations in treatment decisions.

**Core Concept**
Gastrointestinal stromal tumors (GISTs) are driven by mutations in **KIT (CD117)** or **PDGFRA (platelet-derived growth factor receptor alpha)** genes. These mutations lead to constitutive activation of tyrosine kinase receptors, promoting uncontrolled cell proliferation. **KIT mutations account for ~85% of GISTs**, while PDGFRA mutations occur in ~5–10% of cases.

**Why the Correct Answer is Right**
KIT (CD117) is a receptor tyrosine kinase expressed in interstitial cells of Cajal. Somatic mutations in the KIT gene (e.g., exon 11, 9, 13, or 17) cause ligand-independent activation, driving tumorigenesis. These mutations are detected in ~95% of GISTs, making KIT the most common genetic alteration in this tumor type. Targeting KIT with tyrosine kinase inhibitors (e.g., imatinib) is the cornerstone of GIST therapy.

**Why Each Wrong Option is Incorrect**
**Option A:** BRAF mutations are associated with

✓ Correct Answer: A. c-KIT oncogene